metaPreg - Ziprasidone during pregnancy

Ziprasidone updated on 06-10-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.09 [0.81, 1.46]	-	1 study			not evaluable	ROB	-
Congenital heart defects	0.83 [0.45, 1.54]	-	1 study			not evaluable	ROB	-
Gastroschisis	1.89 [0.27, 13.32]	-	1 study			not evaluable	ROB	-
Hip dislocation and/or dysplasia	0.85 [0.12, 6.03]	-	1 study			not evaluable	ROB	-
Major congenital malformations	1.09 [0.81, 1.46]	-	1 study			not evaluable	ROB	-
Oro-facial clefts	2.01 [0.65, 6.22]	-	1 study			not evaluable	ROB	-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Gestational diabetes	0.76 [0.29, 2.00]	-	1 study	26	167	not evaluable	ROB	-
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	1.97 [1.20, 3.24]	-	1 study	114,325	41	not evaluable	ROB	3.35 [1.68; .]
Hide endpoints reported in only one study ...